PFEPfizerSigning up patients
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung (NSCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 714 (planned)
- Started
- Jul 23, 2025
- Main results expected
- Sep 5, 2028
- Fully finished
- Mar 1, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Baseline to date of death from any cause (Approximately 2 years).
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Measured over: From Baseline to to date of first documentation of progression OR death (Approximately 2 years).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06758401 · record last updated 2026-09-25 · checked 2026-11-09 15:36 UTC